このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

YiChang HEC ChangJiang Pharmaceutical 将来の成長

Future 基準チェック /06

YiChang HEC ChangJiang Pharmaceuticalは収益が増加すると予測されています。

主要情報

n/a

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長	10.7%
収益成長率	3.3%
将来の株主資本利益率	19.6%
アナリストカバレッジ	Low
最終更新日	12 May 2024

今後の成長に関する最新情報

Recent updates

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%

May 29

Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?

Apr 23

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce

Mar 01

Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%

Mar 01

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't

Jan 03

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt

Sep 25

Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?

Nov 25

Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?

Mar 23

Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?

Oct 29

Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden

Apr 13

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially

Mar 23

YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.

Mar 13

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?

Feb 20

Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?

Feb 02

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Dec 26

Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend

Dec 13

What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Nov 30

業績と収益の成長予測

SEHK:1558 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	6,982	N/A	N/A	N/A	1
12/31/2025	6,824	N/A	N/A	N/A	1
12/31/2024	6,651	N/A	N/A	N/A	1
12/31/2023	6,295	1,993	1,078	1,673	N/A
9/30/2023	5,978	1,566	1,604	2,233	N/A
6/30/2023	5,661	1,139	2,130	2,792	N/A
3/31/2023	4,703	608	1,488	2,246	N/A
12/31/2022	3,745	77	847	1,700	N/A
9/30/2022	2,875	-18	108	826	N/A
6/30/2022	2,005	-113	-630	-48	N/A
3/31/2022	1,459	-351	-936	-355	N/A
12/31/2021	914	-588	-1,242	-663	N/A
9/30/2021	690	-436	-1,544	-582	N/A
6/30/2021	467	-285	-1,845	-501	N/A
3/31/2021	1,407	277	-1,232	399	N/A
12/31/2020	2,348	839	-619	1,299	N/A
9/30/2020	3,792	1,204	-23	1,688	N/A
6/30/2020	5,236	1,568	574	2,076	N/A
3/31/2020	5,730	1,743	348	1,935	N/A
12/31/2019	6,224	1,919	122	1,794	N/A
9/30/2019	5,162	1,598	-282	1,468	N/A
6/30/2019	4,099	1,276	-686	1,141	N/A
3/31/2019	3,305	1,109	-534	928	N/A
12/31/2018	2,510	943	-381	715	N/A
9/30/2018	2,466	961	-15	878	N/A
6/30/2018	2,422	980	351	1,041	N/A
3/31/2018	2,012	813	325	856	N/A
12/31/2017	1,602	647	300	671	N/A
9/30/2017	1,325	557	N/A	546	N/A
6/30/2017	1,048	467	N/A	422	N/A
3/31/2017	995	424	N/A	409	N/A
12/31/2016	942	381	N/A	397	N/A
9/30/2016	904	354	N/A	391	N/A
6/30/2016	866	327	N/A	385	N/A
3/31/2016	779	297	N/A	336	N/A
12/31/2015	693	266	N/A	287	N/A
9/30/2015	637	236	N/A	196	N/A
6/30/2015	581	207	N/A	104	N/A
3/31/2015	511	171	N/A	117	N/A
12/31/2014	441	135	N/A	130	N/A
12/31/2013	316	58	N/A	52	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 1558の予測収益成長が貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: 1558の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: 1558の収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: 1558の収益 ( 3.3% ) Hong Kong市場 ( 7.8% ) よりも低い成長が予測されています。

高い収益成長: 1558の収益 ( 3.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 1558の自己資本利益率は、3年後には低くなると予測されています ( 19.6 %)。

YiChang HEC ChangJiang Pharmaceutical 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2023

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2021

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2021

Analysts lower EPS estimates to CN¥1.44

Recent updates

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

YiChang HEC ChangJiang Pharmaceutical Co., Ltd., Annual General Meeting, Jun 07, 2024

Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?

Full year 2023 earnings released: EPS: CN¥2.26 (vs CN¥0.087 in FY 2022)

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Investor sentiment deteriorates as stock falls 17%

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce

Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't

Investor sentiment improves as stock rises 23%

Investor sentiment improves as stock rises 16%

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Receives Approval for Mixed Protamine Human Insulin Injection from the China National Medical Products Administration

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.Approves Announces Executive Changes

First half 2023 earnings released: EPS: CN¥1.17 (vs CN¥0.037 loss in 1H 2022)

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 31, 2023

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Announces Resignation of Chen Yangui as Executive Director

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2023

GUO Meilan and ZHANG Yushuai completed the acquisition of 9.9134% stake in Sunshine Lake Pharma Co., Ltd. from YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (SEHK:1558).

Full year 2022 earnings released: EPS: CN¥0.087 (vs CN¥0.67 loss in FY 2021)

Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?

Less than half of directors are independent

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Announces Insulin Aspart 30 Injection Approves for Launch

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Approves to Launch Insulin Aspart Injection

Yichang Hec Changjiang Pharmaceutical Co., Ltd. Announces Committee Appointments

Yichang Hec Changjiang Pharmaceutical Co., Ltd. Announces Resignation of Eddy Huang as Non-Executive Director and Independent Non-Executive Director

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.58 loss in 1H 2021)

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. to Report First Half, 2022 Results on Aug 26, 2022

Less than half of directors are independent

YiChang HEC ChangJiang Pharmaceutical Co., Ltd., Annual General Meeting, Jun 02, 2022

Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Announces Azithromycin Tablets Obtained Approval to Launch from the China National Medical Products Administration

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Announces Executive Changes

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Announces Metoprolol Succinate Sustained-Release Tablets Approved to Launch

Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?

First half 2021 earnings released: CN¥0.58 loss per share (vs CN¥0.70 profit in 1H 2020)

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2021

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2021

Investor sentiment deteriorated over the past week

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Announces Approval for Launch of Atorvastatin Calcium Tablets

Investor sentiment improved over the past week

Yichang Hec Changjiang Pharmaceutical Co., Ltd. Announces Approval for Launch of Aripiprazole Orally Disintegrating Tablets

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Announces Febuxostat Tablets Approved to Launch

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.95 (vs CN¥2.16 in FY 2019)

Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially

Full year 2020 earnings released

YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

Investor sentiment improved over the past week

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Receives Approval Notice from the National Medical Products Administration Relating to Registration for Domestic Production of Insulin Aspart 30 Injection

Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?

New 90-day low: HK$8.44

New 90-day low: HK$8.83

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Update on Assessment and Approval Process of Emitasvir Phosphate Capsules (0.1g)

Analysts lower EPS estimates to CN¥1.44

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend

What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Yichang Hec Changjiang Pharmaceutical Co., Ltd. Announces Ticagrelor Tablets Approved to Launch

Market pulls back on stock over the past week

New 90-day low: HK$8.94

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Receives Approval Notice from the National Medical Products Administration

New 90-day low: HK$9.30

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Appoints Li Xuechen as an Independent Non-Executive Director

New 90-day low: HK$10.52

First half earnings released

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (SEHK:1558) completed the acquisition of Guangdong Hec Biological Preparation Co., Ltd. from Shenzhen Hec Industrial Development Limited.